CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

NCT03113188 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: CBP501

Sponsor

CanBas Co. Ltd.